Their pivotal efforts have helped develop standard approaches to these cancers. Clinicians see 200 new patients a year, offer more than 20 open research protocols, and enroll 150 plus patients annually in research studies. Specialized areas of research and treatment include:
- Interleukin-2 based therapy
- Vaccines, cytokines and other immunotherapies
- Angiogenesis and signal transduction inhibitors
- Pro-apoptotic agents to promote programmed cell death
Research study grants from NIH, foundations and industry support this ground breaking work, as do two National Cancer Institute (NCI)-sponsored SPORE grants in skin and kidney cancer as a member of the Dana-Farber/Harvard Cancer Center (DF/HCC).
Patients with melanoma and kidney cancer who require surgical care are treated in our Skin/Cutaneous Oncology and Kidney Tumor programs.
Our Biologic Therapy Program is Internationally recognized for contributions to the biologic treatment of cancer using cytokines (IL-2,1 FN), targeted immunotherapy (CTLA4 and PD1 antibodies), vaccines and other novel agents.